PROGRESS AT LAST?: REVIEWING RECENTLY UPDATED ACCF/AHA HEART FAILURE GUIDELINES
|
|
- Bruce Rose
- 5 years ago
- Views:
Transcription
1 PROGRESS AT LAST?: REVIEWING RECENTLY UPDATED ACCF/AHA HEART FAILURE GUIDELINES Jon Linder, Pharm.D. PGY1 Pharmacy Resident Iowa City VA Health Care System Objectives for Pharmacists Summarize the burden of heart failure on hospitals and healthcare costs Explain the pathophysiology of heart failure using the neurohormonal model Recommend sacubitril/ and ivabradine appropriately for patients in the context of other guidelinedirected medication therapy and patient characteristics Outline how to appropriately switch from an ACE-inhibitor or ARB to sacubitril/ Counsel patients on the potential side effects of ivabradine and sacubitril/ Objectives for Technicians Distinguish between the four ACCF/AHA Stages of Heart Failure Identify drugs recommended in the 2013 ACCF/AHA guidelines for Stage C Heart Failure with Reduced Ejection Fraction (HFrEF) Summarize how ivabradine affects heart rate Explain how to appropriately transition from an ACEinhibitor or ARB to sacubitril/ Epidemiology of Heart Failure (HF) United States: Lifetime risk for HF is 2 ~5.7 million Americans have HF Prognosis: ~5 mortality rate at 5 years post-diagnosis Roughly 1 in 9 deaths list HF as contributing factor Incidence = around 650,000 new cases/year Incidence increases with age ~20/1000 people years old >80/1000 people >85 years old Loehr et al. Am J Cardiol Mozzafarian et al. Circulation Heart Failure Hospital Burden Primary diagnosis in over 1 million hospitalizations each year in the United States Those hospitalized with HF symptoms are at high risk for re-hospitalization 25% of patients are readmitted to the hospital within 1 month of HF hospitalization Total cost of HF care is >$30 billion annually 5 consists of hospital costs Mean cost of one HF hospitalization was $23,077 in 2013 Go, et al. Ciculation Circ Cardiovasc Qual Outcomes Description of Heart Failure Structural or functional damage Impairs ventricular filling or ejection of blood from heart Typical symptoms include dyspnea, fatigue, and edema Heart failure with reduced ejection fraction (HFrEF): Patients with an ejection fraction (EF) 4 Most drug trials only enroll patients with HFrEF Heart failure with preserved ejection fraction (HFpEF): Generally, EF of at least 5 Subcategories: Borderline: EF = 41-49% Improved: Previously had HFrEF, but now has EF above ACCF/AHA HF guidelines. Circulation. 1
2 Classifications of Heart Failure ACCF/AHA Stages of Heart Failure A B C D High risk for HF, but no structural heart disease or symptoms Structural heart disease but no signs or symptoms of HF NYHA Functional Classification N/A I No symptoms of HF, even with moderate physical activity Structural heart disease, with symptoms of HF currently or in the past II Slight limitation; Symptoms of HF with moderate physical activity Refractory HF III IV Marked limitation; Symptoms of HF w/ mild physical activity Symptoms with any physical activity, or at rest Adapted from: 2013 ACCF/AHA HF guidelines. Circulation. Causes of Structural Change Tissue death Coronary artery disease (myocardial infarction) Certain chemotherapy (anthracyclines, trastuzumab) Tachycardia Atrial fibrillation Pressure overload Hypertension Aortic stenosis Goldberg. Ann Intern Med ACCF/AHA HF guidelines. Circulation. Pathophysiology of Heart Failure Neurohormonal Model (Theoretical) Bio-active molecules have toxic effects on heart/circulatory system, which worsens heart failure Toxicity from bio-active molecules leads to more left ventricle dysfunction and hemodynamic instability Release of bio-active molecules to promote hemodynamic stability Neurohormones (Bio-active molecules) Angiotensin II Aldosterone Norepinephrine Endothelin Neprilysin (Natriuretic peptides) Current drugs and their targets: Sympathetic nervous system (Beta-blockers) Renin-Angiotensin-Aldosterone System or RAAS (ACE-inhibitors/ARBs and aldosterone antagonists) Natriuretic peptides (neprilysin inhibitors) Mann. Circulation Mann. Circulation ACCF/AHA Practice Guideline 2013 ACCF/AHA Guideline for the Management of Heart Failure Comprehensive guidelines published October 15, 2013 in Circulation Jointly produced by the American College of Cardiology Foundation and the American Heart Association since 1980 Recommendations based on committee s perpetual literature review Cost is a factor, but secondary to efficacy and outcomes Application of Recommendations Size of Treatment Effect: Class I Class IIa Class IIb Class III Benefit clearly outweighs risk; Treatment SHOULD be prescribed Level of Evidence: Benefit outweighs risk, more focused studies needed REASONABLE to prescribe Benefit Risk MAY CONSIDER prescribing Level A Level B Level C Based on multiple randomized clinical trials or meta-analysis Based on single randomized trial or several non-randomized studies No benefit and/or possible harm DO NOT prescribe Based on consensus expert opinion, case studies, or standard of care Adapted from 2013 ACCF/AHA HF guidelines. Circulation. 2
3 HFrEF Stage C Treatment: Review of 2013 Treatment Recommendations (Stage C HFrEF) Volume overloaded, NYHA class II-IV patients ACE-inhibitor or ARB AND a Beta-Blocker* Persistently symptomatic African-American patients, NYHA Class III-IV All NYHA class II-IV patients, (CrCl >30mL/min and K+ <5mEq/dL) Loop Diuretic Class I, LOE C *Carvedilol, bisoprolol, and metoprolol succinate are the only 3 approved for HF Hydralazine- Nitrates Aldosterone Antagonist Adapted from 2013 ACCF/AHA HF guidelines. Circulation. Other Medications Digoxin no mortality benefit; option for patients optimized on guideline based therapy to reduce hospitalizations (Class IIa; LOE B) Which of the following medications have not been shown to reduce mortality in heart failure? Anticoagulation not recommended for heart failure in the absence of other indication (Class III; LOE B) Statins no benefit for heart failure alone (Class III; LOE A) Avoid antiarrythmics, NSAIDs, thiazolidinediones, and calcium channel blockers (Class III; LOE B) A. Carvedilol B. Propranolol C. Digoxin D. Furosemide 2013 ACCF/AHA HF guidelines. Circulation Focused Update on New Pharmacotherapy (Stage C HFrEF) (Corlanor ) 3
4 Basics of the Sinoatrial (SA) Node Natural pacemaker Other heart cells are stable during diastole; SA node cells intrinsically depolarize during diastole until reaching the threshold for another action potential Depolarization likely due to the I f current Very slow onset and offset Activated by hyperpolarization Mechanism of Action Inhibits hyperpolarization-activated cyclic nucleotide gated channels (f-channels) Disrupts the I f current (funny current) Increases length of diastole (slowing heart rate), without lowering firing threshold for an action potential Only binds to channel during depolarization phase Permeable to sodium and potassium Nawarskas. Cardiology in Review Nawarskas. Cardiology in Review and Outcomes in Chronic Heart Failure Karl Swedberg, et al. Lancet 2010; 376: ,558 patients w/ symptomatic heart failure and EF 35%, in sinus rhythm, with heart rate 70bpm Randomized, double-blind, placebo-controlled, parallel-group Composite Endpoint: CV Mortality or HF Hospitalization 3 2 HR 0.82 p< NNT=24 24% 29% Intervention Primary endpoint 1 ivabradine titrated to max 7.5mg twice daily vs placebo composite of CV death or heart failure hospitalization Swedberg. Lancet Swedberg. Lancet
5 3 2 1 HF Hospitalization HR 0.74 p< NNT=22 16% 21% CV Mortality HR 0.91 p=0.128 NNT=84 14% 15% Adverse Effect (%) (%) p value All serious adverse effects Symptomatic bradycardia 5 1 < Asymptomatic bradycardia 6 1 < Atrial fibrillation Phosphenes 3 1 < Swedberg. Lancet Swedberg. Lancet Pharmacodynamics Heart rate reduction with ivabradine is use-dependent Effects more pronounced at higher heart rates Heart rate reduction limited to 18-2 of baseline Using recommended doses between 2.5 to 7.5mg twice daily Average reduction of 10 bpm at rest and during activity No significant effects on contractility Berdeaux. Drugs European Medicines Agency Pharmacokinetics Absorption 4 bioavailable (first pass elimination) Exposure 20-4 greater when taken with food Metabolism CYP3A4 extensively metabolized to equipotent active metabolite (metabolite also metabolized by CYP3A4) Avoid concomitant use with potent CYP3A4 inducers/inhibitors Elimination 4% unchanged renally Effective half life = 6 hours Corlanor product information Contraindications Acute decompensated heart failure Strong CYP3A4 inhibitors Patients dependent on pacemaker Heart rate <60 bpm before treatment Severe hepatic impairment (Child Pugh Class C) Profound hypotension (<90/50mmHg) Sick sinus syndrome, sinoatrial block, third-degree atrioventricular block Corlanor product information Counseling and Monitoring Typical dose is 5mg twice daily; Always take with food Side effects: bradycardia, atrial fibrillation, visual changes Avoid driving until patient has adjusted to ivabradine Avoid during pregnancy At 2 weeks, adjust based on heart rate Resting rate >60bpm: by 2.5mg twice daily (MAX 7.5mg twice daily) Resting rate <50bpm: by 2.5mg twice daily Patients >75 years old: start at 2.5mg twice daily Corlanor product information
6 Patient Case 80 yo white M returning to clinic for HF follow up; no new complaints The provider consults you, the pharmacist, and you deduce the patient is inquiring about ivabradine Over the holidays, a friend told him about a new HF pill to lower heart rate (pretty sure it was called Eleanor ) PMH: CAD, HFrEF (NYHA Class II), HTN, GERD, h/o CABG (last echocardiogram was 3 months ago; EF = 33%) Vitals: BP 134/88mmHg, P 86, 88kg PE: chronic SOB (unchanged today), trace edema in legs Meds: omeprazole 20mg daily, furosemide 20mg daily, atorvastatin 40mg daily, losartan 50mg daily, spironolactone 25mg daily, aspirin 81mg daily, carvedilol 3.125mg twice daily (started 1 month ago) What is the most appropriate response? A. Your heart rate is still elevated, so this might be a good time for you to start taking ivabradine. This is a great drug that can help you live longer and frankly everyone should be taking it. B. One of your current drugs is made to lower your heart rate, and we have room to keep increasing the dose. It actually has more benefits than ivabradine and is going to be much more affordable. C. Your heart rate today looks great! We probably don t need to change anything today. Sacubitril and (Entresto ) Natriuretic Peptide System Three peptides: atrial natriuretic peptide (ANP), B-type natriuretic peptide (BNP), C-type natriuretic peptide (CNP) ANP, BNP, and CNP activate cgmp as a second messenger Each have cardiorenal protective properties ANP and BNP are not adequately activated in heart failure and hypertension Neprilysin breaks down ANP, BNP, and CNP Mangiafico. Eur Heart J Cardiomyocyte Extracellular Endothelial Cell cgmp-mediated Effects ANP BNP CNP Natriuresis Antihypertrophic Guanylyl cyclase A PDE phosphodiesterase PKG protein kinase G cgmp cyclic guanosine monophosphate cgmp Intracellular Guanylyl cyclase B PDE PKG Adapted from Fig 2, Mangiafico. Eur Heart J Inhibition of renin and aldosterone Anti-apoptosis Lipolysis Vascular regeneration Anti-fibrotic effects Vasodilation Mangiafico. Eur Heart J
7 Angiotensin-Neprilysin Inhibition Versus in Heart Failure 8442 patients w/ class II-IV HF and EF 4; BNP >150pg/mL; stable dose of a beta-blocker and an ACE/ARB; GFR >30mL/min; no history of angioedema or severe hypotension Randomized, double-blind, active comparator, parallel-group McMurray, et al. New England Journal of Medicine Sept 2014; 371: Intervention sacubitril/ 97/103mg BID vs enalapril 10mg BID Primary endpoint CV death or first HF hospitalization Study Design Run-in Run-in Study Switched from current ACE/ARB to single-blind dose of enalapril 10mg twice daily for 2 weeks Switched from enalapril to sacubitril/ for 4-6 weeks Target doses: Sacubitril/ 97/103mg twice daily vs enalapril 10mg twice daily Composite Endpoint: CV Mortality or 1 st HF Hospitalization HR 0.80 p<0.001 NNT= 22 22% Sacubitril/ Sacubitril/ 27% st HF Hospitalization HR 0.79 p<0.001 NNT=36 13% 16% CV Mortality HR 0.80 p<0.001 NNT = 32 13% 17% Adverse Effect Sacubitril/ (%) (%) p value Symptomatic hypotension <0.001 Serum creatinine >2.5mg/dL Serum potassium >6mmol/L Sacubitril/ Sacubitril/ Sacubitril/ Sacubitril/ Cough <0.001 Angioedema
8 Sacubitril Pharmacodynamics Prodrug: active metabolite is a Neprilysin inhibitor Inhibits the breakdown of vasoactive peptides by neprilysin Blocks breakdown of ANP, BNP, and CNP (cardioprotective) Blocks breakdown of endothelin-1 and angiotensin I (increased RAAS activity and net vasoconstriction) Blocks breakdown of bradykinin (increases angioedema risk) Sacubitril/ Pharmacodynamics Valsartan (angiotensin receptor blocker) added to block the inherent increase in RAAS activity caused by sacubitril ARBs cause less increase of bradykinin than ACE inhibitors, less risk of angioedema in combination w/ sacubitril Sacubitril retains the added benefit of blocking the breakdown of cardio-protective ANP, BNP, and CNP Mangiafico. Eur Heart J Mangiafico. Eur Heart J Sacubitril/ Pharmacokinetics Absorption Valsartan component more bioavailable than other formulations (thus lower dose in the combination pill) Metabolism Sacubitril converted to active metabolite via plasma esterase Valsartan minimal metabolism Elimination Valsartan 13% renal, 86% fecal; half life= 9.9 hours Sacubitril metabolite 6 renal, 4 fecal; effective half life= 11.5h Entresto product information Dosing Starting dose is sacubitril 24mg/ 26mg twice daily for those without prior ACE or ARB (or low doses of either) Starting dose for those with prior ACE or ARB is sacubitril 49mg/ 51mg twice daily Target dose is sacubitril 97mg/ 103mg twice daily, doubling the dose every 2-4 weeks as tolerated CrCl <30mL/min or moderate hepatic impairment = start at lowest dose twice daily Entresto product information Counseling and Monitoring If switching from an ACE inhibitor: Must allow 36-hour washout period before starting sacubitril/ Black Box Warning: avoid in pregnancy (ARB) Side effects: hypotension 18%, hyperkalemia 12%, renal failure 5%, angioedema 0.5% Monitor serum creatinine and potassium after several weeks, periodically thereafter Entresto product information Cost Effectiveness Studies Several analyses conducted based on PARADIGM-HF All found similar results $45,000 to $51,000 per Quality Adjusted Life Year (QALY) Driven by increased average survival Based on wholesale acquisition price of $4,560/year for sacubitril/ Potential for 3000 fewer hospitalizations and deaths per 100,000 patients receiving sacubitril/ over 2 years Reduced HF admissions amount to >$27 million saved Treatment most cost effective in NYHA Class II patients Gaziano. JAMA Cardiol Sandhu. Ann Intern Med
9 Formulary Status HFrEF Stage C Treatment: Typically Tier 3 Preferred Brand Name Drug Most private insurers, including Medicare Part D plans Coinsurance ranges from 30-5 ACE-inhibitor or ARB fdsdfasdf AND a Beta-Blocker Transition from ACE/ARB to Sacubitril/ Class I, LOE B Copays ranging from $ per month Prior Authorization Volume overloaded, NYHA class II-IV patients Persistently symptomatic African-American patients, NYHA Class III-IV All NYHA class II-IV patients, (CrCl >30mL/min and K+ <5mEq/dL) 18 or older, on max tolerated beta-blocker, with no angioedema history Stabilized on ACE/ARB for four weeks prior to starting Prescribed by cardiologist Quantity Limits (60 tablets/month) Entresto Drug Policy. Wellmark Medicare Plan Finder. Medicare.gov. Wellmark BlueRX Complete Formulary Loop Diuretic Class I, LOE C Hydralazine- Nitrates Aldosterone Antagonist Adapted from 2013 ACCF/AHA HF guidelines. Circulation. Case Continued Despite not recommending the use of ivabradine, you encourage the provider to switch from losartan to sacubitril/. You meet with the patient to provide counseling. What counseling points are important to discuss? (select all appropriate answers) A. Take this drug twice daily B. Dose will be titrated every 5 to 7 days C. The most common side effect is low blood pressure D. Stop the losartan and wait 2 days before starting sacubitril/ Updates: Quick Reference Class LOE Recommendation IIa B: RCT can reduce risk of HF hospitalization. Must have heart rate above 70 beats per minute despite maximum-tolerated beta-blocker I B: RCT NYHA Class II or III: patients tolerating ACE inhibitor or ARB should be switched to sacubitril/ to further reduce morbidity and mortality III B: RCT Sacubitril/ should not be used within 36 hours of last dose of an ACE inhibitor III C: Expert Opinion Sacubitril/ should not be started in patients with history of angioedema Summary >$30 billion spent on HF yearly (5 for hospitalizations) RAAS, sympathetic nervous system, and neprilysin all cause HF progression works only at the sinoatrial node to prolong diastole and thus slow heart rate = only if heart rate >70 and on max tolerated beta-blocker Sacubitril adds to mortality benefit by blocking neprilysin s breakdown of cardio-protective natriuretic peptides Guidelines recommend switching ACE/ARB patients to sacubitril/ if no angioedema history (must wait 36 hours to start) Both drugs dosed twice daily and titrated to max tolerated dose LOE = Level of Evidence RCT = Randomized Controlled Trial Focused Updates. Circulation
Disclosures. This speaker has indicated there are no relevant financial relationships to be disclosed.
Disclosures This speaker has indicated there are no relevant financial relationships to be disclosed. And the Beat Goes On: New Medications for Heart Failure Alison M. Walton, PharmD, BCPS The Case of
More informationHEART FAILURE: PHARMACOTHERAPY UPDATE
HEART FAILURE: PHARMACOTHERAPY UPDATE 3 HEART FAILURE REVIEW 1 5.1 million x1.25 = 6.375 million 40 years old = MICHAEL F. AKERS, PHARM.D. CLINICAL PHARMACIST CENTRACARE HEALTH, ST. CLOUD HOSPITAL HF Diagnosis
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More information1/4/18. Heart Failure Guideline Review and Update. Disclosure. Pharmacist Objectives. Pharmacy Technician Objectives. What is Heart Failure?
Disclosure Heart Failure Guideline Review and Update I have had no financial relationship over the past 12 months with any commercial sponsor with a vested interest in this presentation. Natalie Beiter,
More informationSacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure. Elizabeth Pogge, PharmD, MPH, BCPS, FASCP
Sacubitril/valsartan: A New Management Strategy for the Treatment of Heart Failure Elizabeth Pogge, PharmD, MPH, BCPS, FASCP Disclosure Elizabeth Pogge reports no actual or potential conflicts of interest
More informationBeyond ACE-inhibitors for Heart Failure. Jacob Townsend, MD NCVH Birmingham 2015
Beyond ACE-inhibitors for Heart Failure Jacob Townsend, MD NCVH Birmingham 2015 % Decrease in Mortality Current Therapy HFrEF 0% Angiotensin receptor blocker ACE inhibitor Beta blocker Mineralocorticoid
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationHeart Failure: Current Management Strategies
Heart Failure: Current Management Strategies CSHP Fall Education Session- September 30th, 2017 Carolyn MacKinnon & Tamara Matchett BscPharm, ACPR Candidates Objectives 1. Describe the pathophysiology &
More informationWhat s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital
What s New in Heart Failure? Marie-France Gauthier, BSc, PharmD, ACPR Clinical Pharmacist at Montfort Hospital Disclosures I have no current or past relationships with commercial entities Learning objectives
More informationRationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients
Rationale and Practical Aspects of Sacubitril- Valsartan and Ivabradine Use in Heart Failure Patients Javed Butler, MD, MPH, MBA Patrick H. Lehan Professor of Medicine Professor of Physiology Chairman,
More informationNeprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary
Neprilysin Inhibitor (Entresto ) Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1 Indication Entresto Reduce the risk of cardiovascular (sacubitril/valsartan) death
More informationLong-Term Care Updates
Long-Term Care Updates July 2015 By Amy Friedman Wilson, PharmD Heart failure (HF) is a clinical condition in which ventricular filling or ejection of blood is structurally or functionally impaired. 1
More informationARxCH. Annual Review of Changes in Healthcare. Entresto: An Overview for Pharmacists
Entresto: An Overview for Pharmacists David Comshaw, PharmD Candidate 2019 1 Gyen Musgrave, PharmD Candidate 2019 1 Suzanne Surowiec, PharmD, BCACP 1 Jason Guy, PharmD 1 1 University of Findlay College
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationContemporary Management of Heart Failure. Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium
Contemporary Management of Heart Failure Keerthy K Narisetty, MD Comprehensive Heart Failure Management Program BHHI Primary Care Symposium Disclosures I have no relevant relationships with commercial
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationNew Winners in the World of Heart Failure. Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015
New Winners in the World of Heart Failure Laura Steffens PharmD Candidate 2016 CICU Presentation August 12, 2015 Jessup 2014 Shaking Things Up 2003: FDA approved eplerenone for the treatment of heart failure
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationState-of-the-Art Management of Chronic Systolic Heart Failure
State-of-the-Art Management of Chronic Systolic Heart Failure Michael McCulloch, MD 17 th Annual Cardiovascular Update Intermountain Medical Center December 16, 2017 Disclosures: I have no financial disclosures
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationAkash Ghai MD, FACC February 27, No Disclosures
Akash Ghai MD, FACC February 27, 2015 No Disclosures Epidemiology Lifetime risk is > 20% for American s older than 40 years old. > 650,000 new cases diagnosed each year. Incidence increases with age: 2%
More informationHeart Failure 101 The Basic Principles of Diagnosis & Management
Heart Failure 101 The Basic Principles of Diagnosis & Management Bill Tran, MD Non Invasive Cardiologist February 24, 2018 What the eye does not see and the mind does not know, does not exist. DH Lawrence
More information2/15/2017. Disclosures. Heart Failure = Big Problem. Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017
Heart Failure Update Reducing Hospitalizations and Improving Patient Outcomes 02/18/2017 Julio A. Barcena, M.D. South Miami Heart Specialists Disclosures I have no relevant commercial relationships to
More informationHeart Failure. Subjective SOB (shortness of breath) Peripheral edema. Orthopnea (2-3 pillows) PND (paroxysmal nocturnal dyspnea)
Pharmacology I. Definitions A. Heart Failure (HF) Heart Failure Ezra Levy, Pharm.D. HF Results when one or both ventricles are unable to pump sufficient blood to meet the body s needs There are 2 types
More informationHeart Failure Medical and Surgical Treatment
Heart Failure Medical and Surgical Treatment Daniel S. Yip, M.D. Medical Director, Heart Failure and Transplantation Mayo Clinic Second Annual Lakeland Regional Health Cardiovascular Symposium February
More informationEstimated 5.7 million Americans with HF. 915, 000 new HF cases annually, HF incidence approaches
Heart Failure: Management of a Chronic Disease Jenny Bauerly RN, CHFN, APRN-BC Heart Failure (HF) Definition A complex clinical syndrome that can result from any structural or functional cardiac disorder
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Neprilysin Inhibitor (Entresto ) Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Neprilysin Inhibitor (Entresto ) Prime Therapeutics will review Prior
More informationDisclosure Statement. Heart Failure: Refreshers and Updates. Objectives. CHF: Chronic Heart Failure. Definitions. Definitions 2/19/2018
Disclosure Statement Heart Failure: Refreshers and Updates Tracy K. Pettinger, PharmD Clinical Associate Professor College of Pharmacy The planners and presenter of this presentation have disclosed no
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationClinical Pearls Heart Failure Cardiology/New Drugs
Clinical Pearls Heart Failure Cardiology/New Drugs Friday, September 9 th, 2016 Heidi Burres, PharmD, BCACP MTM Pharmacist Fairview Pharmacy Services Thank You to XYZ Event Sponsor(s): Wi-fi Information:
More informationHeart Failure New Drugs- Updated Guidelines
Heart Failure New Drugs- Updated Guidelines Eileen Handberg, PhD, ANP-BC, FAHA, FACC Professor of Medicine Division of Cardiovascular Medicine University of Florida Disclosures 1. 3 2. 6 3. 8 4. 11 Dunlay
More informationHeart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none
Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationCORLANOR (ivabradine) oral tablet
CORLANOR (ivabradine) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage
More informationIntroduction to Heart Failure. Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL
Introduction to Heart Failure Mauricio Velez, M.D. Transplant Cardiologist APACVS 2018 April 5-7 Miami, FL Disclosures No relevant financial relationships to disclose Objectives and Outline Define heart
More informationSummary/Key Points Introduction
Summary/Key Points Introduction Scope of Heart Failure (HF) o 6.5 million Americans 20 years of age have HF o 960,000 new cases of HF diagnosed annually o 5-year survival rate for HF is ~50% Classification
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationHeart Failure Update. Bibiana Cujec MD May 2015
Heart Failure Update Bibiana Cujec MD May 2015 Disclosures Participation in clinical trial GUIDE IT (BNP in management of HF) Plan Review of new trials/ccs guidelines Management of heart failure: cases
More informationHeart Failure (HF) Treatment
Heart Failure (HF) Treatment Heart Failure (HF) Complex, progressive disorder. The heart is unable to pump sufficient blood to meet the needs of the body. Its cardinal symptoms are dyspnea, fatigue, and
More informationENTRESTO (sacubitril and valsartan) oral tablet
ENTRESTO (sacubitril and valsartan) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More information2016 Update to Heart Failure Clinical Practice Guidelines
2016 Update to Heart Failure Clinical Practice Guidelines Mitchell T. Saltzberg, MD, FACC, FAHA, FHFSA Medical Director of Advanced Heart Failure Froedtert & Medical College of Wisconsin Stages, Phenotypes
More informationSystolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine
Systolic Dysfunction Clinical /Hemodynamic Guide for Management From Neprilysin Inhibitors to Ivabradine Donna Mancini MD Choudhrie Professor of Cardiology Columbia University Speaker Disclosure Amgen
More informationREVIEW ARTICLE. Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2
Sacubitril/valsartan Use for the Hospitalist Mitchell Padkins 1, James Hart 1, Rachel Littrell 2 1 University of Missouri School of Medicine, Columbia, MO 2 Division of Cardiovascular Medicine, Department
More information2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much?
2017 CCS HF Guidelines Medical Therapy for HFrEF When What Order and How Much? Dr. Shelley Zieroth University of Manitoba @ShelleyZieroth @CanHFSociety Disclosures Consulting/Advisory Board: Amgen, Astra
More information2/3/2017. Objectives. Effective Heart Failure Management through Evidence Based Practice and Innovation
Effective Heart Failure Management through Evidence Based Practice and Innovation Jennifer Bauerly RN, CHFN, APRN-BC CentraCare Heart and Vascular Center Objectives Describe the scope and impact of heart
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More informationKnown Actions of Digoxin
Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (
More informationCardiovascular Pharmacotherapy
Cardiovascular Pharmacotherapy Overview Mechanism of cardiovascular drugs Indications and clinical use in cardiology Renin-Angiotensin Inhibitors: Angiotensin-Converting Enzyme Inhibitors, Angiotensin
More informationNew Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD
New Agents for Heart Failure: Ivabradine Jeffrey S. Borer, MD Professor of Medicine, Cell Biology, Radiology and Surgery Director, The Howard Gilman Institute for Heart Valve Disease and the Schiavone
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationHeart Failure: Guideline-Directed Management and Therapy
Heart Failure: Guideline-Directed Management and Therapy Guideline-Directed Management and Therapy (GDMT) was developed by the American College of Cardiology and American Heart Association to define the
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationHeart Failure. Dr. William Vosik. January, 2012
Heart Failure Dr. William Vosik January, 2012 Questions for clinicians to ask Is this heart failure? What is the underlying cause? What are the associated disease processes? Which evidence-based treatment
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationHeart Failure CTSHP Fall Seminar
Heart Failure CTSHP Fall Seminar Laurajo Ryan, PharmD, MSc, BCPS, CDE Pharmacist Learning Objectives Outline the pathophysiology of heart failure List triggers for decompensated heart failure Describe
More informationUpdate in Congestive Hear Failure DRAGOS VESBIANU MD
Update in Congestive Hear Failure DRAGOS VESBIANU MD Case 58 yo AAM c/o shortness of breath for 3 weeks. Used to walk one mile per day and now he has noticed that he gets short of breath after 2 blocks.
More informationHow Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs?
How Do You Mend a Broken Heart: The New Agents to Treat HF Paradigm Shift or Just the Same Old Drugs? Gregg C. Fonarow, MD FACC, FAHA, FHFSA Co-Chief UCLA Division of Cardiology Director, Ahmanson-UCLA
More informationGuideline-Directed Medical Therapy
Guideline-Directed Medical Therapy Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation OPTIMAL THERAPY (As defined in
More informationOverview & Update on the Utilization of the Natriuretic Peptides in Heart Failure
June 28, 2016 Overview & Update on the Utilization of the Natriuretic Peptides in Heart Failure Linda C. Rogers, PhD, DABCC, FACB. Agenda Overview of the Natriuretic Peptides and Efficacy studies Similarities
More informationAZMARDA Tablets (Sacubitril/Valsartan)
Published on: 20 Mar 2017 AZMARDA Tablets (Sacubitril/Valsartan) Composition AZMARDA 50 Each film-coated tablet contains: 24 mg sacubitril and 26 mg valsartan as sodium salt complex AZMARDA 100 Each film-coated
More informationInitiating New Medications in the Management of Heart Failure
Initiating New Medications in the Management of Heart Failure Sandra Oliver-McNeil DNP, MSN, ACNP-BC, CHFN Associate Professor (Clinical) Wayne State University College of Nursing Objectives The participant
More informationHeart Failure Pharmacotherapy An Update
Heart Failure Pharmacotherapy An Update Kenneth Mishler, PharmD, MBA Objectives Review the epidemiology of heart failure (HF) Review evidence based guidelines for the use of mediations used to treat HF
More informationEntresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction
Cardio-Metabolic Franchise Entresto Development of sacubitril/valsartan (LCZ696) for the treatment of heart failure with reduced ejection fraction Randy L Webb, PhD Rutgers Workshop October 21, 2016 Heart
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationHEART FAILURE KEEPING YOUR PATIENT AT HOME
HEART FAILURE KEEPING YOUR PATIENT AT HOME SUZANNE FRAZIER MS, CRNP, NP-C, CHFN HEART FAILURE DISEASE MANAGEMENT COORDINATOR PENN STATE HERSHEY HEART & VASCULAR INSTITUTE IMPACT OF HEART FAILURE In 2010,
More informationOptimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists
Optimizing CHF Therapy: The Role of Digoxin, Diuretics, and Aldosterone Antagonists Old Drugs for an Old Problem Jay Geoghagan, MD, FACC BHHI Primary Care Symposium February 28, 2014 None. Financial disclosures
More informationSystolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges
Systolic Dysfunction Clinical/Hemodynamic Guide for Management; New Medical and Interventional Therapeutic Challenges Clyde W. Yancy, MD, MSc, FACC, FAHA, MACP Magerstadt Professor of Medicine Professor,
More informationManagement Strategies for Advanced Heart Failure
Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology
More informationHeart Failure Medications: Who Needs What Drug Now? Disclosures
Heart Failure Medications: Who Needs What Drug Now? Simon Jackson MD FRCPC MMedEd Professor of Medicine (Cardiology) Dalhousie 1 Disclosures Honoraria and educational grants from: Actelion (medications
More informationWhat Next? Management of Heart Failure with Reduced Ejection Fraction What Does the Evidence Show Us?
65 yr WM presents for followup of HFrEF. Management of Heart Failure with Reduced Ejection Fraction What Does the Evidence Show Us? NYHA II-III, HFH 6 mo ago. Prior CABG, DM and HTN. LVEF 30%. Meds: lisinopril
More informationHeart Failure: Combination Treatment Strategies
Heart Failure: Combination Treatment Strategies M. McDonald MD, FRCP State of the Heart Symposium May 28, 2011 None Disclosures Case 69 F, prior MIs (LV ejection fraction 25%), HTN No demonstrable ischemia
More informationPCSK9 INHIBITORS, ARNIS, FUNNY CHANNEL INHIBITORS: ARE YOU SURE THESE ARE REALLY CARDIAC DRUGS?
PCSK9 INHIBITORS, ARNIS, FUNNY CHANNEL INHIBITORS: ARE YOU SURE THESE ARE REALLY CARDIAC DRUGS? ALLORIE SMITH, PHARM.D. CARDIOVASCULAR UPDATE CONFERENCE FEBRUARY 9, 2012 OBJECTIVES Explain the pharmacology
More informationHEART FAILURE-UPDATES AND PRACTICAL APPROACHES TO PATIENT CARE
HEART FAILURE-UPDATES AND PRACTICAL APPROACHES TO PATIENT CARE DR DEAN T. GOROSKI, BCPS, CAPT, USPHS 2018 MPA WINTER CE AND SKI MEETING BIG SKY, MT JANUARY 6, 2018 DISCLOSURE Dr. Goroski has no actual,
More informationANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD
ANGIOTENSIN RECEPTOR-NEPRILYSIN INHIBITORS IN HEART FAILURE FROM CHD Karen Stout, MD FACC Professor, Medicine/Pediatrics University of Washington Seattle, WA USA No disclosures Case 35 year old man with
More informationHeart Failure October 8, 2011
HFrEF Michael Muellerleile M.D. Goals of Presentation Touch on pathophysiology of chronic systolic heart failure Review assessment and outpatient pharmacologic management of HFrEF Highlight non-pharmacologic
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest
More informationCardiovascular Clinical Practice Guideline Pilot Implementation
Cardiovascular Clinical Practice Guideline Pilot Implementation Pharmacologic Management of Chronic Heart Failure Sept 15, 2004 Angela Allerman, PharmD, BCPS DoD Pharmacoeconomic Center Promoting high
More informationLCZ696 A First-in-Class Angiotensin Receptor Neprilysin Inhibitor
The Angiotensin Receptor Neprilysin Inhibitor LCZ696 in Heart Failure with Preserved Ejection Fraction The Prospective comparison of ARNI with ARB on Management Of heart failure with preserved ejection
More informationManagement of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA
Management of chronic heart failure: pharmacology. Giuseppe M.C. Rosano, MD, PhD, FHFA Declaration of potential conflict of interests Type of job or financial support Salary Ordinary funds Position in
More informationPharmacology. Update. Learning Objectives. Learning Objectives. for Advanced Practice Nurses
Pharmacology Update for Advanced Practice Nurses Trish Freeman, RPh, PhD Associate Professor, Pharmacy Practice and Science University of Kentucky College of Pharmacy University of Southern Indiana September
More informationWhat s at the Heart of the Matter?
What s at the Heart of the Matter? Inpatient Pharmacy Services for Heart Failure Patients Jason Williamson, PharmD, BCPS Clinical Pharmacy Manager, PGY1 Pharmacy Residency Director Genesys Regional Medical
More informationHeart Failure Update Hope or Hype?
Heart Failure Update Hope or Hype? Laurajo Ryan, PharmD, MSc, BCPS, CDE Clinical Associate Professor The University of Texas at AusFn College of Pharmacy University of Texas Health Science Center Pharmacotherapy
More informationDefinition of Congestive Heart Failure
Heart Failure Definition of Congestive Heart Failure A clinical syndrome of signs & symptoms resulting from the heart s inability to supply adequate tissue perfusion. CHF Epidemiology Affects 4.7 million
More informationDISCLOSURES ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION NONE
ACHIEVING SUCCESS THROUGH FAILURE: UPDATE ON HEART FAILURE WITH PRESERVED EJECTION FRACTION Lori M. Tam, MD Providence Heart Institute DISCLOSURES NONE 1 OUTLINE Systolic vs. Diastolic Heart Failure New
More informationDisclosure of Relationships
Disclosure of Relationships Over the past 12 months Dr Ruilope has served as Consultant and Speakers Bureau member of Astra-Zeneca, Bayer, Daiichi-Sankyo, Menarini, Novartis, Otsuka, Pfizer, Relypsa, Servier
More informationCongestive Heart Failure 2015
Definition Congestive Heart Failure 215 JP Mehegan/ Mercy Cardiology n Cardiac failure; Congestive heart failure; Chronic heart failure (synonyms) n When the heart is unable to pump sufficiently and at
More informationNew Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition
New Paradigms in Rx of Symptomati Heart Failure:Role of Ivabradine & Angiotensin Neprilysin Inhibition Prakash Deedwania, MD, FACC, FACP, FCCP, FAHA Professor of Medicine, UCSF School of Medicine, Director,
More informationBalanced information for better care. Heart failure: Managing risk and improving patient outcomes
Balanced information for better care Heart failure: Managing risk and improving patient outcomes Heart failure increases hospitalization Heart failure is the most common medical reason for hospitalization
More informationNew Advances in the Diagnosis and Management of Acute and Chronic Heart Failure
New Advances in the Diagnosis and Management of Acute and Chronic Heart Failure Deborah Budge, MD Intermountain Healthcare Heart Failure Cardiologist Objectives: State the updates from the ACC 2013 HF
More informationWhat s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA
What s new in the 2017 heart failure guidelines Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA Key points to remember 2017 guidelines recommend using natriuretic peptides as biomarkers to screen for heart
More informationAntialdosterone treatment in heart failure
Update on the Treatment of Chronic Heart Failure 2012 Antialdosterone treatment in heart failure 전남의대윤현주 Chronic Heart Failure Prognosis of Heart failure Cecil, Text book of Internal Medicine, 22 th edition
More informationHeart Failure Therapies State of the Art 2017
Heart Failure Therapies State of the Art 2017 Andrew J. Sauer, MD Assistant Professor Director, Center for Heart Failure Medical Director, Heart Transplantation UNOS Primary Transplant Physician asauer@kumc.edu
More informationPatient details GP details Specialist details Name GP Name Dr Specialist Name Dr R. Horton
Rationale for Initiation, Continuation and Discontinuation (RICaD) Sacubitril/Valsartan (Entresto) For the treatment of symptomatic heart failure with reduced ejection fraction (NICE TA388) This document
More information